TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
There is considerable interest in harnessing innate immunity to treat Alzheimer’s disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG4 Fc (sTLR5Fc) results in robust attenuation of amyloid β (Aβ) accumulation in a mouse model of Alzheimer-type Aβ pathology. sTLR5Fc binds to oligomeric and fibrillar Aβ with high affinity, forms complexes with Aβ, and blocks Aβ toxicity. Oligomeric and fibrillar Aβ modulates flagellin-mediated activation of human TLR5 but does not, by itself, activate TLR5 signaling. Genetic analysis shows that rare protein coding variants in human TLR5 may be associated with a reduced risk of AD. Further, transcriptome analysis shows altered TLR gene expression in human AD. Collectively, our data suggest that TLR5 decoy receptor–based biologics represent a novel and safe Aβ-selective class of biotherapy in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 1×
“TLRs are pattern recognition receptors of the innate immune system that are activated by pathogen- (PAMP) or damage-associated molecular patterns (DAMPs; Kawai and Akira, 2011).”
BackgroundAn anatomically comprehensive atlas of the adult human brain transcriptome
Hawrylycz, M. J., Lein, E. S., Guillozet-Bongaarts, A. L., Shen, E. H., Ng, L., Miller, J. A., van de Lagemaat, L. N., Smith, K. A., Ebbert, A., Riley, Z. L., et al. (2012) · Nature · doi:10.1038/nature11405 · Cited by 3,083
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 1×
“Experimental studies in transgenic mouse models with AD-like pathologies demonstrate that manipulating innate immune pathways can have positive or negative effects on AD proteostasis, cognition, and neurodegeneration (Heneka et al., 2015; Heppner et al., 2015), a phenomenon we have collectively termed immunoproteostas…”
BackgroundStewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., Rayner, K. J., Boyer, L., Zhong, R., Frazier, W. A., et al. (2010) · Nature Immunology · doi:10.1038/ni.1836 · Cited by 1,513
Negative regulation of Toll-like receptor-mediated immune responses
Liew, F. Y., Xu, D., Brint, E. K., & O'Neill, L. A. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1630 · Cited by 1,509 · cited 3×
“Overall, given there is precedence of sTLRs as a preclinical therapeutic in dampening systemic inflammation (Liew et al., 2005; Henrick et al., 2016), the significance of our”
BackgroundAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Self-citationAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“TLRs are pattern recognition receptors of the innate immune system that are activated by pathogen- (PAMP) or damage-associated molecular patterns (DAMPs; Kawai and Akira, 2011).”
BackgroundIn vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · cited 1×
“Aggregation was performed in 10 mM HCl, whereas oligomerization was performed in phenol red–free Ham’s F12 media as described earlier (Stine et al., 2003).”
MethodTherapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“Compared with pharmacological TLR inhibitors or antagonists (Kanzler et al., 2007), this approach utilizes the essential beneficial component of innate immune activation, i.”
BackgroundRegulation of innate immune responses in the brain
Rivest, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2565 · Cited by 843 · cited 3×
“RNA sequencing (RNAseq) shows TLR upregulation in AD patient brains Previous studies have suggested that select TLRs may regulate immunoproteostasis in AD models (Rivest, 2009); however, TLR expression networks have not been systematically studied in human AD.”
BackgroundInfluentialRemoving technical variability in RNA-seq data using conditional quantile normalization
Hansen, K. D., Irizarry, R. A., & WU, Z. (2012) · Biostatistics · doi:10.1093/biostatistics/kxr054 · Cited by 607
CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3158-09.2009 · Cited by 591 · cited 1×
“AD-associated amyloid β (Aβ) aggregates appear to be DAMPs and can interact with and activate endogenous pattern recognition receptors, including a complex of TLR2, CD14, and TLR4, resulting in chronic inflammatory activation (Liu et al., 2005; Reed-Geaghan et al., 2009; Stewart et al., 2010).”
BackgroundSperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · cited 1×
“An important aspect to consider in anti-Aβ therapeutics that have immunomodulatory functions are the inherent safety issues; immunomodulatory therapies could have significant side effects that might limit their use in an aged population (Sperling et al., 2012).”
BackgroundRole of toll-like receptor signalling in A uptake and clearance
Tahara, K., Kim, H.-D., Jin, J.-J., Maxwell, J. A., Li, L., & Fukuchi, K.-I. (2006) · Brain · doi:10.1093/brain/awl249 · Cited by 493 · cited 2×
“Based on previous data that Aβ interacts with select TLRs (Liu et al., 2005; Tahara et al., 2006), we hypothesized that soluble ectodomains of select human TLRs could be used as decoy receptors to bind and alter Aβ and AD-like phenotypes in an APP transgenic model (TgCRND8; Janus et al., 2000).”
BackgroundA Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · cited 1×
“Notably, the strength of this binding was similar to many of the high-affinity monoclonal anti-Aβ antibodies used in current AD immunotherapies (Levites et al., 2006a; Adolfsson et al., 2012; Demattos et al., 2012; Miles et al., 2013; Wisniewski and Goñi, 2015; Sevigny et al., 2016).”
ResultIdentifying Recent Adaptations in Large-Scale Genomic Data
Grossman, S. R., Andersen, K. G., Shlyakhter, I., Tabrizi, S., Winnicki, S., Yen, A., Park, D. J., Griesemer, D., Karlsson, E. K., Wong, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.035 · Cited by 368
Chakrabarty, P., Li, A., Ceballos-Diaz, C., Eddy, J. A., Funk, C. C., Moore, B., DiNunno, N., Rosario, A. M., Cruz, P. E., Verbeeck, C., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.11.020 · Cited by 354
Self-citationChakrabarty, P., Jansen‐West, K., Beccard, A., Ceballos‐Diaz, C., Levites, Y., Verbeeck, C., Zubair, A. C., Dickson, D., Golde, T. E., & Das, P. (2010) · The FASEB Journal · doi:10.1096/fj.09-141754 · Cited by 328
Self-citationAdolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317
Matarin, M., Salih, D. A., Yasvoina, M., Cummings, D. M., Guelfi, S., Liu, W., Nahaboo Solim, M. A., Moens, T. G., Paublete, R. M., Ali, S. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.041 · Cited by 290
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · cited 1×
“Notably, the strength of this binding was similar to many of the high-affinity monoclonal anti-Aβ antibodies used in current AD immunotherapies (Levites et al., 2006a; Adolfsson et al., 2012; Demattos et al., 2012; Miles et al., 2013; Wisniewski and Goñi, 2015; Sevigny et al., 2016).”
ResultA Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274
Convergent genetic and expression data implicate immunity in Alzheimer's disease
International Genomics of Alzheimer's Disease Consortium (IGAP), Jones, L., Lambert, J., Wang, L., Choi, S., Harold, D., Vedernikov, A., Escott‐Price, V., Stone, T., Richards, A., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.05.1757 · Cited by 199
Self-citationMiles, L. A., Crespi, G. A. N., Doughty, L., & Parker, M. W. (2013) · Scientific Reports · doi:10.1038/srep01302 · Cited by 130 · cited 1×
“Notably, the strength of this binding was similar to many of the high-affinity monoclonal anti-Aβ antibodies used in current AD immunotherapies (Levites et al., 2006a; Adolfsson et al., 2012; Demattos et al., 2012; Miles et al., 2013; Wisniewski and Goñi, 2015; Sevigny et al., 2016).”
ResultThakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124 · cited 1×
“…system delivery of a biological therapy may have several advantages, including (1) limiting peripheral side effects; (2) reducing potential for immune responses against the biologic; and (3) enhancing efficacy by increasing exposure in the target organ (Levites et al., 2006b; Thakker et al., 2009).”
BackgroundInsights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 116 · cited 4×
“The effect sizes of sTLR5/sTLR5Fc for reducing biochemical amyloid loads as reported here are among the strongest reported to date in the TgCRND8 model of Aβ deposition (Janus et al., 2000; Levites et al., 2006a,b).”
BackgroundMethodResultSelf-citationIFN‐γ promotes τ phosphorylation without affecting mature tangles
Li, A., Ceballos‐Diaz, C., DiNunno, N., Levites, Y., Cruz, P. E., Lewis, J., Golde, T. E., & Chakrabarty, P. (2015) · The FASEB Journal · doi:10.1096/fj.15-275834 · Cited by 43 · cited 1×
“Primary neuroglial cultures Primary neuroglia was prepared from cerebral cortices of wildtype mice as described earlier (Li et al., 2015).”
MethodSelf-citationHanna, A., Iremonger, K., Das, P., Dickson, D., Golde, T., & Janus, C. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt124 · Cited by 38
Self-citation
Cited by
Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program
Geirsdottir, L., David, E., Keren-Shaul, H., Weiner, A., Bohlen, S. C., Neuber, J., Balic, A., Giladi, A., Sheban, F., Dutertre, C.-A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.11.010 · Cited by 496
Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms
De, S., Wirthensohn, D. C., Flagmeier, P., Hughes, C., Aprile, F. A., Ruggeri, F. S., Whiten, D. R., Emin, D., Xia, Z., Varela, J. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09477-3 · Cited by 448
Toll-like receptors in the pathogenesis of neuroinflammation
Kumar, V. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.03.012 · Cited by 331
β-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia
Friker, L. L., Scheiblich, H., Hochheiser, I. V., Brinkschulte, R., Riedel, D., Latz, E., Geyer, M., & Heneka, M. T. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.025 · Cited by 191
“Moreover, Ab has been shown to modulate flagellin-mediated activation but does not by itself activate TLR5 signaling (Chakrabarty et al., 2018).”
BackgroundZhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229819 · Cited by 157
“Alzheimer’s brain and soluble fragments have been shown to act as decoy receptors to ameliorate disease phenotypes in a transgenic mouse model of AD [46].”
Background
Metadata
- Authors
- Chakrabarty, P., Li, A., Ladd, T. B., Strickland, M. R., Koller, E. J., Burgess, J. D., Funk, C. C., Cruz, P. E., Allen, M., Yaroshenko, M., Wang, X., Younkin, C., Reddy, J., Lohrer, B., Mehrke, L., Moore, B. D., Liu, X., Ceballos-Diaz, C., Rosario, A. M., Medway, C., Janus, C., Li, H.-D., Dickson, D. W., Giasson, B. I., Price, N. D., Younkin, S. G., Ertekin-Taner, N., & Golde, T. E.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2018-08-29
- Volume
- 215
- Issue
- 9
- Pages
- 2247-2264
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2888826632
- Cited by
- 78
- References
- 29
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.